文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌放疗中有临床意义症状的漏报:是否因患者特征而异?

Underascertainment of Clinically Meaningful Symptoms During Prostate Cancer Radiation Therapy-Does This Vary by Patient Characteristics?
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-02-02

该研究在前列腺或前列腺床接受调强放疗的544例连续患者中,前瞻性比较患者报告结局(PRO)与医生CTCAE分级对7项泌尿和胃肠道症状的记录。结果显示85.3%的患者至少1项症状被漏报,PRO报告有临床意义症状的评估占16.9%,而CTCAE仅3.4%,约5倍差异;未婚、农村居住、被监禁、退休/失业、接受前列腺(而非前列腺床)治疗及同期激素治疗者漏报更常见,>70岁者漏报较少。

要点

  • 前列腺癌放疗中85.3%患者至少1项有临床意义症状被医生漏报。
  • PRO报告有临床意义症状的评估占16.9%,CTCAE仅3.4%,约5倍差异。
  • 未婚、农村、被监禁、退休/失业、前列腺治疗及同期激素治疗者漏报风险更高。

核心结论

  • 前列腺癌放疗常规临床 care 中存在有临床意义症状的漏报,且某些患者群体更易被漏报。
  • 结果强调将PRO纳入放疗患者临床 care 的重要性,若未常规使用PRO,脆弱群体需额外关注。

研究设计与样本

  • 前瞻性收集2010至2018年544例连续接受前列腺或前列腺床调强放疗患者的每周治疗访视及首次治疗后随访数据。
  • 使用经验证的前列腺癌症状指数患者报告结局(PRO)和CTCAE医生分级同步评估7项泌尿和胃肠道症状。
  • 漏报定义为PRO提示有临床意义症状而医生CTCAE评估未记录。
  • 采用单因素和多因素logistic回归分析与漏报相关的患者特征。

主要发现

  • 总体85.3%的患者至少1项症状被漏报。
  • 按PRO评估,16.9%的评估报告有临床意义症状,而CTCAE仅3.4%,约5倍差异。
  • 多因素分析显示未婚(OR 1.28;95%CI 1.18-1.38)、农村居住(OR 1.10;95%CI 1.01-1.21)、被监禁(OR 1.58;95%CI 1.36-1.84)、退休/失业(OR 1.29;95%CI 1.18-1.40)、接受前列腺(vs前列腺床)治疗(OR 1.43;95%CI 1.31-1.58)及同期激素治疗(OR 1.16;95%CI 1.04-1.29)者漏报更常见。
  • 年龄>70岁者较<60岁者漏报更少(OR 0.82;95%CI 0.73-0.92)。

临床怎么用

  • 在前列腺癌放疗临床 care 中应纳入PRO以准确评估和管理毒性。
  • 若未常规使用PRO,应对未婚、农村居住、被监禁、退休/失业、接受前列腺治疗及同期激素治疗等脆弱群体额外关注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: It is well known that physicians underascertain chemotherapy-related toxicity compared with patient self-report. However, symptom underascertainment in radiation therapy and characterization of patient groups at increased risk for underascertainment have not been examined. METHODS AND MATERIALS: As part of routine clinical care, 7 urinary and gastrointestinal symptoms were prospectively collected with both patient-report outcomes (PROs) using the validated Prostate Cancer Symptom Indices and physician-graded symptoms using Common Terminology Criteria for Adverse Events (CTCAE) for 544 consecutive patients from 2010 to 2018 who received intensity modulated radiation therapy to the prostate or prostate bed. Data from weekly treatment visits and the first posttreatment follow-up were analyzed. Underascertainment was defined as an occurrence when a clinically meaningful symptom was indicated on PROs but not physician CTCAE assessment. Univariate and multivariable logistic regression examined characteristics associated with underascertainment. RESULTS: Overall, 85.3% of patients had underascertainment of at least 1 symptom. Per PRO, 16.9% of assessments reported clinically meaningful symptoms, in contrast to only 3.4% per CTCAE, representing an approximate 5-fold difference. Multivariable analysis showed underascertainment was more common in patients who were unmarried (odds ratio [OR] 1.28; 95% confidence interval [CI], 1.18-1.38), lived in rural regions (OR 1.10; 95% CI, 1.01-1.21), incarcerated (OR 1.58; 95% CI, 1.36-1.84), retired/unemployed (OR 1.29; 95% CI, 1.18-1.40), received prostate gland (vs prostate bed) treatment (OR 1.43; 95% CI, 1.31-1.58), and received concurrent hormone therapy (OR 1.16; 95% CI, 1.04-1.29). Patients age >70 years were less likely to have underascertainment compared with those age <60 years (OR 0.82; 95% CI, 0.73-0.92). CONCLUSIONS: This is the first study to show underascertainment of clinically meaningful symptoms in radiation therapy patients in routine clinical care and further to demonstrate that certain patient groups are especially vulnerable to underascertainment. These results highlight the importance of incorporating PROs in the clinical care of radiation therapy patients. If PROs are not routinely used, vulnerable patient groups may need additional attention during cancer treatment to ensure accurate toxicity assessment and management.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Sud S, Gerringer BC, Wacaser BS, et al. Underascertainment of Clinically Meaningful Symptoms During Prostate Cancer Radiation Therapy-Does This Vary by Patient Characteristics? Int J Radiat Oncol Biol Phys. 2021. PMID: 33539967. doi:10.1016/j.ijrobp.2021.01.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。